## HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

	PATIENT:
Name:	Name:
Ward:	NHI:
Sapropterin	ihydrochloride
Prerequisites	required after 1 month ck boxes where appropriate) bed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health spital.
and on an analysis of an analysis o	reatment with sapropterin is required to support management of PKU during pregnancy reproperties to be administered at doses no greater than a total daily dose of 20 mg/kg reproperties to be used alone or in combination with PKU dietary management reproperties to be used alone or in combination with PKU dietary management reproperties to be used alone or in combination with PKU dietary management reproperties to be used alone or in combination with PKU dietary management
	regnant) and treatment will be stopped after delivery  required after 12 months ck boxes where appropriate)
Re-assessmer Prerequisites	required after 12 months ck boxes where appropriate) bed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health
Re-assessmer Prerequisites  Prese NZ H	required after 12 months ck boxes where appropriate) bed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health
Re-assessmer Prerequisites Press NZ H and	equired after 12 months ck boxes where appropriate)  bed by, or recommended by a metabolic physician, or in accordance with a protocol or guideline that has been endorsed by the Health spital.  Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy  On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and